Esperion Expands Coverage for NEXLETOL and NEXLIZET
Esperion Therapeutics has made significant progress in improving patient access to its products, NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), by updating its commercial and Medicare formulary coverage. As a result, the company now provides coverage for more than 136 million commercially insured individuals and around 34 million Medicare beneficiaries throughout the United States. This impressive reach represents 92% of all commercially insured patients and 65% of those on Medicare.
Increased Coverage and Improved Access
The recent review and approval of expanded treatment options have led numerous insurance providers and major pharmacy benefit managers to update their utilization management criteria, reflecting the findings from the CLEAR Outcomes trial. Sheldon Koenig, President and CEO of Esperion, expressed his satisfaction with this development, noting that the clinical data has instilled renewed confidence in healthcare providers when prescribing NEXLETOL and NEXLIZET.
Significance of NEXLETOL and NEXLIZET
NEXLETOL and NEXLIZET stand out as the only non-statin medications approved by the FDA for lowering LDL cholesterol levels and reducing the risk of cardiovascular events, including myocardial infarction and the need for coronary revascularization. These medications are particularly beneficial for both primary and secondary prevention patients, offering essential options for those who cannot tolerate statin therapy.
Prescribing Eased for Healthcare Providers
The recent changes in coverage also mean that prior authorization processes have been streamlined. Consequently, healthcare providers can now prescribe NEXLETOL and NEXLIZET with greater ease, which enhances the management of patients with high cholesterol. This adjustment is advantageous for patients who need to lower their LDL-C levels to effectively prevent heart disease.
Important Safety Information
As with any medication, it is important to be aware of the safety precautions associated with NEXLETOL and NEXLIZET. Both products are contraindicated for individuals with a history of hypersensitivity to their components. Potential risks, including tendon ruptures, hyperuricemia leading to gout, and various adverse reactions, should be closely monitored. Regular assessments of uric acid levels are recommended throughout treatment, especially for patients with a history of gout or tendon disorders.
Common side effects reported during clinical trials have included upper respiratory tract infections, abdominal discomfort, and muscle spasms. It is essential for healthcare providers to discuss these potential side effects with their patients to facilitate informed decision-making regarding their treatment options.
The Mission of Esperion Therapeutics
Esperion Therapeutics is dedicated to transforming cardiovascular care through the development of effective treatments. Their mission focuses on addressing the needs of millions of individuals with high cholesterol who have not had adequate therapeutic options in the past. By empowering healthcare providers to achieve cholesterol targets as effectively as possible, Esperion aims to improve outcomes for those at risk of cardiovascular diseases.
Contact Information for Inquiries
For additional inquiries, Esperion offers several communication channels. Interested individuals can contact them via email for investor relations at investorrelations@esperion.com. Media inquiries can be directed to Tiffany Aldrich at corporateteam@esperion.com or by phone at (616) 443-8438.
Frequently Asked Questions
What are NEXLETOL and NEXLIZET used for?
NEXLETOL and NEXLIZET are FDA-approved non-statin medications designed to lower LDL cholesterol levels in patients with cardiovascular conditions.
How has coverage for these medications changed?
Recent updates have expanded coverage to over 136 million commercially insured lives and 34 million Medicare lives across the U.S.
What safety information should be noted?
Patients should be aware of potential risks such as tendon rupture and hyperuricemia, and regular monitoring is recommended.
Can healthcare providers prescribe these medications easily now?
Yes, the new coverage includes improved prior authorization processes that facilitate easier prescribing for healthcare providers.
How can I contact Esperion for more information?
Inquiries can be directed to their investor relations email or the media contact provided on their website.
